File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Conference Paper: The value of tranexamic acid in orthognathic surgery

TitleThe value of tranexamic acid in orthognathic surgery
Authors
Issue Date2015
PublisherChurchill Livingstone. The Journal's web site is located at http://www.elsevier.com/locate/ijom
Citation
The 22nd International Conference on Oral and Maxillofacial Surgery (ICOMS 2015), Melbourne, Australia, 27-30 October 2015. In International Journal of Oral and Maxillofacial Surgery, 2015, v. 44 suppl. 1, p. e3 How to Cite?
AbstractOrthognathic Surgery is a common procedure for the correction of dentofacial deformity. It may be associated with significant blood loss especially in bimaxillary osteotomies with segmentalization. Different haemostatic measures have been advocated including the use of hypotensive anaesthesia and haemostastic agents such as aprotinin, desmopressin, Yunnan baiyao. Tranexamic acid (TA) is a lysine analogue which acts as a clot stabilizer. It has been marketed for decades and it is an affordable drug. Several clinical trials were carried out in the last decade and showed preoperative intravenous bolus of TA could significantly reduce blood loss in orthognathic surgery. Two studies even tried to use TA topically during bimaxillary osteotomy. We performed a randomized controlled trial with 61 patients from 2005 to 2008 and demonstrated a 30% reduction of mean blood loss in patients receiving a single preoperative bolus of TA with standard hypotensive anaesthesia during bimaxillary osteotomy. No adverse event or complication related to the use of TA was found. Although it appeared that TA was cost effective in reducing blood loss in orthognathic surgery, the studies available in the literature were based on small sample size. In the presentation, I will share and discuss our experience of using TA in orthognathic surgery. Analysis of data of 545 cases operated from 2008 to 2015 will be presented.
DescriptionThis journal suppl. entitled: 22nd International Conference on Oral & Maxillofacial Surgery, Melbourne, Australia
Persistent Identifierhttp://hdl.handle.net/10722/232200
ISSN
2015 Impact Factor: 1.563
2015 SCImago Journal Rankings: 0.854

 

DC FieldValueLanguage
dc.contributor.authorChoi, WWS-
dc.date.accessioned2016-09-20T05:28:24Z-
dc.date.available2016-09-20T05:28:24Z-
dc.date.issued2015-
dc.identifier.citationThe 22nd International Conference on Oral and Maxillofacial Surgery (ICOMS 2015), Melbourne, Australia, 27-30 October 2015. In International Journal of Oral and Maxillofacial Surgery, 2015, v. 44 suppl. 1, p. e3-
dc.identifier.issn0901-5027-
dc.identifier.urihttp://hdl.handle.net/10722/232200-
dc.descriptionThis journal suppl. entitled: 22nd International Conference on Oral & Maxillofacial Surgery, Melbourne, Australia-
dc.description.abstractOrthognathic Surgery is a common procedure for the correction of dentofacial deformity. It may be associated with significant blood loss especially in bimaxillary osteotomies with segmentalization. Different haemostatic measures have been advocated including the use of hypotensive anaesthesia and haemostastic agents such as aprotinin, desmopressin, Yunnan baiyao. Tranexamic acid (TA) is a lysine analogue which acts as a clot stabilizer. It has been marketed for decades and it is an affordable drug. Several clinical trials were carried out in the last decade and showed preoperative intravenous bolus of TA could significantly reduce blood loss in orthognathic surgery. Two studies even tried to use TA topically during bimaxillary osteotomy. We performed a randomized controlled trial with 61 patients from 2005 to 2008 and demonstrated a 30% reduction of mean blood loss in patients receiving a single preoperative bolus of TA with standard hypotensive anaesthesia during bimaxillary osteotomy. No adverse event or complication related to the use of TA was found. Although it appeared that TA was cost effective in reducing blood loss in orthognathic surgery, the studies available in the literature were based on small sample size. In the presentation, I will share and discuss our experience of using TA in orthognathic surgery. Analysis of data of 545 cases operated from 2008 to 2015 will be presented.-
dc.languageeng-
dc.publisherChurchill Livingstone. The Journal's web site is located at http://www.elsevier.com/locate/ijom-
dc.relation.ispartofInternational Journal of Oral and Maxillofacial Surgery-
dc.rightsPosting accepted manuscript (postprint): © <year>. This manuscript version is made available under the CC-BY-NC-ND 4.0 license http://creativecommons.org/licenses/by-nc-nd/4.0/-
dc.titleThe value of tranexamic acid in orthognathic surgery-
dc.typeConference_Paper-
dc.identifier.emailChoi, WWS: drwchoi@hku.hk-
dc.identifier.authorityChoi, WWS=rp01521-
dc.identifier.doi10.1016/j.ijom.2015.08.920-
dc.identifier.hkuros264321-
dc.identifier.volume44-
dc.identifier.issuesuppl. 1-
dc.identifier.spagee3-
dc.identifier.epagee3-
dc.publisher.placeUnited Kingdom-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats